All In Biotech

Drug Trial Radar · NCT02117115

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Jun 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Jun 2014

Primary completion

Oct 2014

Study completion May 2015

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
Who can join
All sexes, from 20 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

Conditions

  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute
  • Leukemia, Myelogenous, Chronic
  • Multiple Myeloma

Interventions

  • Dynamic contrast-enhanced computed tomographyRadiation

    CT scan performed between Day +7 and Day +14.

  • IoversolDrug

    To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of contrast related nephropathyTime frame: Baseline through 72 hours after intravenous contrast administration
  2. Incidence of contrast allergic reactionTime frame: Within 4 hours after contrast administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.